Oral Hypoglycemic Agents in the Management of Non-Insulin-Dependent Diabetes Mellitus Among the Elderly

1991 ◽  
Vol 17 (5) ◽  
pp. 411-413 ◽  
Author(s):  
Karen H. McAvoy
Keyword(s):  
Diabetes Mellitus ◽  
Insulin Dependent Diabetes Mellitus ◽  
The Elderly ◽  
Insulin Dependent Diabetes ◽  
Hypoglycemic Agents ◽  
Dependent Diabetes Mellitus ◽  
Oral Hypoglycemic Agents ◽  
Insulin Dependent

scholarly journals Herbal Drugs with Anti-Diabetic Potential

2021 ◽  
Vol 11 (6) ◽  
pp. 248-256
Author(s):  
Smily Walia ◽  
J.S. Dua ◽  
D.N. Prasad
Keyword(s):  
Diabetes Mellitus ◽  
Adverse Effects ◽  
Insulin Dependent Diabetes Mellitus ◽  
Insulin Dependent Diabetes ◽  
Hypoglycemic Agents ◽  
Dependent Diabetes Mellitus ◽  
Oral Hypoglycemic Agents ◽  
The World ◽  
Herbal Plants ◽  
Insulin Dependent

Diabetes mellitus (DM), also known as insulin-dependent diabetes mellitus (IDDM) and non-insulin dependent diabetes mellitus (NIDDM), is a common and serious metabolic condition that affects people all over the world. Traditional herbal plants have been utilized to treat diabetes mellitus all throughout the world. Several herbs have been found to treat and control diabetes among numerous medicines and poly herbal plants; they also have no adverse effects. Diabetes mellitus is a horrible disease that affects people all over the world and is becoming a serious danger to humanity's health.  Thus, herbal plants may be a possible source of anti-diabetic medicines, with ethno botanical data indicating that around 800 plants may have anti-diabetic potential. Although synthetic oral hypoglycemic agents/insulin are a popular diabetes therapy and are effective in controlling hyperglycemia, they have significant side effects and do not significantly modify the course of diabetic complications. This is the primary reason why an increasing number of individuals are looking for alternative medicines with fewer or no adverse effects. The botanical name, common name, component, and mechanism of action for anti-diabetic activity were provided in this review study, as well as plant-based commercial poly herbal formulations. Keywords: Diabetes mellitus, Medicinal plants, glucose, poly herbal plants

scholarly journals A MODERN OVERVIEW ON DIABETES MELLITUS: A CHRONIC ENDOCRINE DISORDER

2020 ◽  
Vol 5 (2) ◽  
pp. 1-14
Author(s):  
Y Mukhtar ◽  
A Galalain ◽  
U Yunusa
Keyword(s):  
Diabetes Mellitus ◽  
Blood Sugar ◽  
Insulin Dependent Diabetes Mellitus ◽  
Insulin Dependent Diabetes ◽  
Hypoglycemic Agents ◽  
Dependent Diabetes Mellitus ◽  
High Blood Sugar ◽  
Type 2 Dm ◽  
Insulin Dependent

Diabetes mellitus is one of the most common endocrine disorders that affect the body’s ability to make or use insulin. Diabetes mellitus (DM), or simply diabetes, is a group of chronic metabolic diseases in which a person experience high blood sugar, either because the pancreas does not produce enough insulin or because the body cells do not effectively use or respond to the insulin that is produced. This high blood sugar produces the classical symptoms of polyuria (frequent urination), polydipsia (increased thirst) and polyphagia (increased hunger). Conventionally, diabetes has been divided into three types namely: Type 1 DM or insulin-dependent diabetes mellitus (IDDM) in which body fails to produce insulin, and presently requires the person to inject insulin or wear an insulin pump. This is also termed as "juvenile diabetes". Type 2 DM or non-insulin-dependent diabetes mellitus (NIDDM), results from insulin resistance, a condition in which cells fail to use insulin properly, with or without an absolute insulin deficiency. This type was previously referred to as or "adult-onset diabetes". The third main type is gestational diabetes which occurs when women without a previous history of diabetes develop a high blood glucose level during her pregnancy and may metamorphose to type 2 DM after giving birth. Currently available pharmacotherapy for the treatment of diabetes mellitus includes insulin and oral hypoglycemic agents. Thus, the present review underscores the issues surrounding the symptoms, diagnosis and treatment (especially use of anti-diabetic herbal species) of this killer disease with a view to suppressing its global spread and resurgence.

Oral health in the elderly with non-insulin-dependent diabetes mellitus

1996 ◽  
Vol 16 (3) ◽  
pp. 116-122 ◽  
Author(s):  
Timo O. Närhi ◽  
Jukka H. Meurman ◽  
D Odont ◽  
Reijo Tilvis ◽  
Anja Ainamo
Keyword(s):  
Diabetes Mellitus ◽  
Oral Health ◽  
Insulin Dependent Diabetes Mellitus ◽  
The Elderly ◽  
Insulin Dependent Diabetes ◽  
Dependent Diabetes Mellitus ◽  
Insulin Dependent

Pharmacokinetics and Pharmacodynamics of Glyburide in Young and Elderly Patients with Non-Insulin-Dependent Diabetes Mellitus

1996 ◽  
Vol 30 (5) ◽  
pp. 472-475 ◽  
Author(s):  
Linda A Jaber ◽  
Edward J Antal ◽  
Ian R Welshman
Keyword(s):  
Diabetes Mellitus ◽  
Insulin Dependent Diabetes Mellitus ◽  
The Elderly ◽  
Insulin Dependent Diabetes ◽  
Dependent Diabetes Mellitus ◽  
Pharmacokinetics And Pharmacodynamics ◽  
Blood Samples ◽  
C Peptide ◽  
Serial Blood ◽  
Insulin Dependent

OBJECTIVE: TO determine the influence of age on the pharmacokinetics and pharmacodynamics of glyburide after acute and chronic dosing in young and elderly subjects with non-insulin-dependent diabetes mellitus. DESIGN: Ten elderly (mean age 69.3 ± 3.1 y) and 10 younger (mean age 45.6 ± 4.5 y) patients received a glucose challenge test at baseline, with a 2.5-mg dose of glyburide at week 0 (acute dose) and again at weeks 6 and 12 of chronic glyburide therapy. Glyburide doses were titrated to a maximum daily dosage of 20 mg to achieve a glucose concentration of 7.8 mmol/L or less. During 24-h pharmacokinetic determinations at weeks 0, 6, and 12, serial blood samples were obtained for glyburide determination with HPLC. Serial blood samples for glucose, insulin, and C-peptide determinations were obtained at baseline (week −1) and at weeks 0, 6, and 12. RESULTS: All pharmacokinetic parameters assessed for glyburide were statistically comparable between the two age groups with the exception of a shorter time to peak concentration in the elderly at weeks 0 and 12. The glucose pharmacodynamic response to glyburide was not statistically different between the two groups. However, there was a statistically significant greater C-peptide response in the elderly group at all evaluation weeks. CONCLUSIONS: Aging appears to have no influence on the pharmacokinetics of glyburide. Observed pharmacodynamic differences indicate the necessity for dosage titration to a specified therapeutic response regardless of patient age.

Sign in / Sign up

Export Citation Format

Share Document